Target intelligence / Profile preview

ADP-ribosylation factor-like protein 4C (ARL4C)

Target
ARL4C
Molecular classification
Small GTPase, ARF family (ADP-ribosylation factor-related GTP-binding protein), Ras superfamily, Actin cytoskeleton regulator
01

Overview

ADP-ribosylation factor-like protein 4C (ARL4C) is a member of the ARF family of small GTP-binding proteins within the Ras superfamily, involved in the regulation of actin cytoskeleton dynamics, cell morphology, migration, and membrane trafficking[1][5]. It localizes to cell membranes, cytoplasm, and nucleus, exhibits unusually high guanine nucleotide exchange rates, and interacts with regulators such as filamin-A and Cdc42 to drive filopodia formation and motility[5]. ARL4C participates in lipid and cholesterol metabolism through LXR-mediated pathways and is implicated in tumor progression, primarily by promoting cancer cell proliferation, migration, and invasion[1][3][5]. Elevated ARL4C expression is associated with cancer aggressiveness, making it both a potential biomarker and a therapeutic target candidate, particularly in renal cell carcinoma and atherosclerosis[1][2][3].

Other names
ARL4CARF-like 7ARL7LAKADP-ribosylation factor-like protein 7ADP-ribosylation factor-like protein LAKADP-ribosylation factor-like 4C
02

Mechanism of action

LXR agonists modulate ARL4C expression and thereby promote cholesterol efflux, alter lipid metabolism. Likely indirect inhibition of cancer cell growth/migration via ARL4C suppression; no direct inhibition described.

03

Biological functions

Signal transductionRegulation of cell morphologyRegulation of cell migrationCytoskeletal remodelingVesicular/membrane traffickingRegulation of cell proliferationBranching morphogenesis (especially in kidney development)Cholesterol efflux and metabolism
04

Disease associations

Cancer (notably renal cell carcinoma, oral squamous cell carcinoma)Atherosclerosis/metabolic disorders involving cholesterolPotential roles in other epithelial tumorigenesis and organ development
05

Safety considerations

No specific safety concerns described; targeting ARL4C may affect cholesterol homeostasis or cytoskeletal integrity, which could impact multiple tissues
06

Interacting drugs

Liver X receptor agonists (e.g., LXR623)
07

Biomarkers

ARL4C expression (mRNA/protein) as a biomarker for cancer cell proliferation, migration, invasion (e.g., in renal cell carcinoma)ARL4C as a potential biomarker for cholesterol efflux capacity and atherosclerosis risk

Beyond the preview

Go deeper on ADP-ribosylation factor-like protein 4C (ARL4C).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADP-ribosylation factor-like protein 4C (ARL4C).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call